Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | TGM6 | O95932 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8325206 | 0.91 | MMP2 (0.48) | LMNABCHEMAOBACHEPTGIR | |
| SCHEMBL3164298 | 0.87 | LMNA (0.41) | ALDH1A1LMNABCHEMAOBACHE | |
| SCHEMBL8320192 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAMMP2MMP9KMT2A | |
| SCHEMBL2958796 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAMMP2MMP9KMT2A | |
| SCHEMBL13201300 | 0.82 | LMNA (0.53) | ALDH1A1LMNAMMP2MMP9KMT2A | |
| SCHEMBL2969347 | 0.82 | LMNA (0.53) | ALDH1A1LMNAMMP2MMP9KMT2A | |
| SCHEMBL8319712 | 0.81 | ATM (0.51) | ALDH1A1LMNAMMP2MMP9KMT2A | |
| SCHEMBL2961185 | 0.81 | ATM (0.51) | ALDH1A1LMNAMMP2MMP9KMT2A | |
| SCHEMBL13201289 | 0.80 | POLB (0.62) | ALDH1A1LMNAKMT2AMEN1GAA | |
| SCHEMBL8319435 | 0.79 | MMP2 (0.48) | ALDH1A1LMNAACHEMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772270-B2 | Imino acid derivatives as inhibitors of matrix metalloproteinases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772270-B2 | Imino acid derivatives as inhibitors of matrix metalloproteinases | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-1585728-B1 | IMINO ACID DERIVATIVES FOR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-20060252752-A1 | Octahydrocyclopenta[b]pyrrole-sulfonamide-2-carboxylic acid derivatives; reduced side effects | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-09 | — | — | US | disclosed |
| EP-1585728-A1 | IMINO ACID DERIVATIVES FOR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | Aventis Pharma Deutschland GmbH (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050004166-A1 | Imino acid derivatives as inhibitors of matrix metalloproteinases | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| WO-2004060874-A1 | IMINO ACID DERIVATIVES FOR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060874-A1 | IMINO ACID DERIVATIVES FOR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004166-A1 | Imino acid derivatives as inhibitors of matrix metalloproteinases | MMP9, MMP1, MMP25 | ALDH1A1 160/4885LMNA 189/4885BCHE 1198/4885 |
| US-20060252752-A1 | Octahydrocyclopenta[b]pyrrole-sulfonamide-2-carboxylic acid derivatives; reduced side effects | SULT2A1, ADCYAP1R1, SULT1A1 | ALDH1A1 155/4885LMNA 4053/4885BCHE 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.